Related Experiment Videos
Hyperparathyroidism and anemia in renal failure.
M Gallieni1, C Corsi, D Brancaccio
1Renal Unit, Ospedale San Paolo, Milan, Italy.
American Journal of Nephrology
|April 25, 2000
Summary
Severe secondary hyperparathyroidism can cause resistance to Epoetin treatment due to bone marrow fibrosis. Effective hyperparathyroidism management may improve anemia, warranting further research.
Area of Science:
- Nephrology
- Endocrinology
- Hematology
Background:
- Severe secondary hyperparathyroidism is linked to osteitis fibrosa and Epoetin resistance.
- Bone marrow fibrosis can impair the response to erythropoiesis-stimulating agents.
Purpose of the Study:
- To investigate the impact of secondary hyperparathyroidism on Epoetin resistance.
- To explore the potential benefits of treating hyperparathyroidism on anemia.
Main Methods:
- Assessing serum parathyroid hormone, calcium, phosphate, and alkaline phosphatase.
- Utilizing skeletal radiology and bone biopsy for diagnosis.
- Evaluating Epoetin response in patients with secondary hyperparathyroidism.
Main Results:
- Secondary hyperparathyroidism, particularly with marrow fibrosis, contributes to Epoetin resistance.
- Treatment of severe secondary hyperparathyroidism may involve active vitamin D or parathyroidectomy.
- Progressive bone marrow unresponsiveness suggests the need for early intervention in metabolic bone disease.
Conclusions:
- Investigating secondary hyperparathyroidism is crucial for unexplained Epoetin resistance.
- Effective treatment of hyperparathyroidism shows promise in improving hemoglobin levels.
- Further controlled studies are needed to confirm these findings and understand underlying mechanisms.